The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-naive patients with benign prostatic hyperplasia
- 作者: Kupriyanov Y.A1,2, Rasner P.I.3,4, Rokhlikov I.M5, Akrikidi A.A6, Soloviev V.V7, Markov A.A8, Nozdrin E.V9, Logvinov L.A10, Vasilevskiy R.P11, Skrupskiy K.S2, Pushkar D.Y.3, Putilovskiy M.A12, Epstein O.I13
-
隶属关系:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia
- Municipal clinical hospital named after S.I. Spasokukotskiy
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Municipal clinical hospital named after S.I. Spasokukotskiy of the Moscow
- GBUZ CP №68 of Moscow Health Department
- GBUZ CP №29 of Moscow Health Department
- GBUZ CP №170 of Moscow Health Department
- GBUZ CP №107 of Moscow Health Department
- GBUZ CP №201 of Moscow Health Department
- GBUZ CP №69 of Moscow Health Department
- GBUZ CP №134 of Moscow Health Department
- NPF «Materia Medica Holding» LTD
- FGBUN Research Institute of General Pathology and Pathophysiology
- 期: 编号 3 (2019)
- 页面: 36-42
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/303633
- DOI: https://doi.org/10.18565/urology.2019.3.36-42
- ID: 303633
如何引用文章
详细
全文:
作者简介
Yu. Kupriyanov
A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia; Municipal clinical hospital named after S.I. Spasokukotskiy
Email: Dr.kupriyanov@gmail.com
Ph.D., assistant at the Department of Urology; urologist
P. Rasner
A.I. Evdokimov Moscow State University of Medicine and Dentistry; Municipal clinical hospital named after S.I. Spasokukotskiy of the Moscow
Email: dr.rasner@gmail.com
MD, professor, MD, professor at the Department of Urology; Head of the Department of Urology №4 Healthcare Department
I. Rokhlikov
GBUZ CP №68 of Moscow Health Department
Email: rohim@urol-androl.ru
Ph.D., urologist and andrologist, chief specialist of Central Administrative Okrug
A. Akrikidi
GBUZ CP №29 of Moscow Health Department
Email: akritas@list.ru
urologist and andrologist, chief specialist of South-East Administrative Okrug
V. Soloviev
GBUZ CP №170 of Moscow Health Department
Email: 1699380@gmail.com
deputy director for clinical work, urologist
A. Markov
GBUZ CP №107 of Moscow Health Department
Email: alek-markov@ya.ru
urologist, Okrug specialist
E. Nozdrin
GBUZ CP №201 of Moscow Health Department
Email: std83@mail.ru
Head of the Department of Urology, urologist
L. Logvinov
GBUZ CP №69 of Moscow Health Department
Email: leolog@rambler.ru
urologist, chief specialist of East Administrative Okrug
R. Vasilevskiy
GBUZ CP №134 of Moscow Health Department
Email: urolog-rv@yandex.ru
urologist, chief specialist of South-West Administrative Okrug
K. Skrupskiy
Municipal clinical hospital named after S.I. Spasokukotskiy
Email: 89_sks@mail.ru
urologist at the Department of Oncourology
D. Pushkar
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: pushkardm@mail.ru
MD, professor, corresponding member of RAS, Chief urologist of the Ministry of Health of Russia and Moscow, General scientific secretary of Russian Society of Urology, Head of the Department of Urology
M. Putilovskiy
NPF «Materia Medica Holding» LTD
Email: putilovskiyma@materiamedica.ru
Ph.D., Director of Clinical and Medical Department
O. Epstein
FGBUN Research Institute of General Pathology and Pathophysiology
Email: epstein@mail.ru
MD, professor, corresponding member of RAS, Head of the Laboratory of physiologically active substances
参考
- Раснер П.И., Газимиев М.А., Гаджиева З.К., Касян Г.Р. Расстройства мочеиспускания у мужчин. Методические рекомендации № 6. М.: ООО «ИД «АБВ-пресс». 2017.С. 35
- Egan K.B. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol. Clin. North. Am. 2016;43:289-297.
- Hutchison A., Farmer R., Verhamme K., Berges R., Navarrete R. V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. European urology. 2007;51(1):207-216.
- Djavan B., Chapple C., Milani S., Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64:1081-1088.
- Emberton M., Cornel E.B., Bassi P.F., Fourcade R.O., Gomez J.M.F., Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int. J. Clin. Pract. 2008;62:1076-1086.
- Oelke M., Bachmann A., Descazeaud A. European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 2013;64:118-140.
- Kolontarev K., Govorov A., Kasyan G., Priymak D., Pushkar D. Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent. European. J. Urol. 2016;69:398-403.
- Pushkar D., Tarasov S., Putilovskiy M. Mild-to-moderate Benign Prostatic Hyperplasia (BPH) symptoms: Filling the gap. 16-th Meeting of the Association of Academic European Urologists (AAEU). Dresden, Germany. December 14-16; 2017. Р. 51-52.
- Fusco F., Palmieri A., Ficarra Кш-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol. 2016;69: 1091-1101.
- Epstein O. The spatial homeostasis hypothesis. Symmetry. 2018;10(4):103. doi: 10.3390/sym10040103.
- Гудков А.В. Опыт длительного применения афалы при доброкачественной гиперплазии предстательной железы. Бюл. экспер. биол. 2009;148(8):57-60
- Эпштейн О.И. Релиз-активность (современный взгляд на гомеопатию и негомеопатию). М.: Издательство РАМН. 2017. 48 с.
- Pushkar D., Vinarov A., Spivak L., Kolontarev K.,PutilovskiyM,Andrianova E., Epstein О. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, doubleblind, placebo-controlled, randomized clinical trial. Central Eur J. Urol. 2018;71:427-435. doi: 10.5173/ceju.2018.1803.
- Mkrtumyan A., Romantsova T., Vorobiev S., Volkova A., Vorokhobina N., Tarasov S., Putilovskiy M., Andrianova E., Epstein O. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 2018;142:1-9.
- Rafalsky V., Averyanov A., Bart B., Minina E., Putilovskiy M., Andrianova E., Epstein O. Efficacy and safety of Ergoferon versus oseltamivir in Adult outpatients with seasonal influenza virus infection: a multicenter open-Label randomized trial. Int J. Infect Dis. 2016;51:47-55.
- Bailbe D., Philippe E., Gorbunov E., Tarasov S., Epstein O., Portha B. The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone. J. Diab Res. 2013;13(1):763125 p. doi: 10.1155/2013/763125.
- Castagne V., Lemaire M., Kheyfets I., Dugina J.L., Sergeeva S.A., Epstein O.I. Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. J. Pharm Pharmacol. 2008;60(3):309-316.
- Chu X., Zhavbert E.S., Dugina Y.L., Kheifets I.A., Sergeeva S.A., Epstein O.I., Agmo A. Sildenafil and a compound stimulating endothelial NO synthase modify sexual incentive motivation and copulatory behavior in male Wistar and Fisher 344 rats. International Society for Sexual Medicine. 2008;5:2085-2099.
- Jacobsen S.J., Jacobson D.J., Girman C.J. etal. Natural History of Prostatism: Risk Factors for Acute Urinary Retention. J. Urol. 1996;155:595-600.
- Roehrborn C.G., McConnell J., Bonilla J. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J. Urol. 2000;163:13-20.
- McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl J. Med. 1998;338:557-563.
- McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl J. Med. 2003;349: 2387-2398.
- Forstermann U., Sessa W.C. Nitric oxide synthases: regulation and function. Eur. Heart. J. 2012;33:829-837.
- Неймарк А.И., Алиев Р.Т., Музалевская Н.И. и др. Использование импазы в лечении эректильной дисфункции у пациентов с гипертонической болезнью и ИБС. Bulletin of Experimental Biology and Medicine. 2009; 148: 328